Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412 · see citing works

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

Stangier, J., Rathgen, K., Stähle, H., & Mazur, D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318170-000000000-00000 · Cited by 720 · see citing works

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate

Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 659 · see citing works

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

Stangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427 · see citing works

Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants

Bannow, B. S., Cuker, A. C., Siegal, D. M., Crowther, M. A., & Garcia, D. A. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.08.1462 · Cited by 347 · see citing works

Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor

Stangier, J., & Clemens, A. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609343004 · Cited by 339 · see citing works

Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement

Stangier, J., Eriksson, B. I., Dahl, O. E., Ahnfelt, L., Nehmiz, G., Stähle, H., Rathgen, K., & Svärd, R. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274550 · Cited by 294 · see citing works

In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate

Stassen, J., Priepke, H. W. M., Ries, U. J., Hauel, N. H., & Wienen, W. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-03-0183 · Cited by 250 · see citing works

Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment

Stangier, J., Stähle, H., Rathgen, K., Roth, W., & Shakeri‐Nejad, K. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008324179 · Cited by 176 · see citing works

Effect of 3.2%vs3.8% Sodium Citrate Concentration on Routine Coagulation Testing

Adcock, D. M., Kressin, D. C., & Marlar, R. A. (1997) · American Journal of Clinical Pathology · doi:10.1093/ajcp/107.1.105 · Cited by 141 · see citing works

Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay

Gerotziafas, G., Depasse, F., Busson, J., Flem, L. L., Elalamy, I., & Samama, M. M. (2005) · Thrombosis Journal · doi:10.1186/1477-9560-3-16 · Cited by 139 · see citing works

Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants

Garcia, D. A., Barrett, Y., Ramacciotti, E., & Weitz, J. I. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12096 · Cited by 117 · see citing works

UDP-Glucuronosyltransferase (UGT) 2B15 Pharmacogenetics: UGT2B15 D85Y Genotype and Gender Are Major Determinants of Oxazepam Glucuronidation by Human Liver

Court, M. H., Hao, Q., Krishnaswamy, S., Bekaii‐Saab, T., Al-Rohaimi, A., Moltke, L. L., & Greenblatt, D. J. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067660 · Cited by 115 · see citing works

Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender

Shi, J., Wang, X., Nguyen, J., Bleske, B. E., Liang, Y., Liu, L., & Zhu, H. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.003 · Cited by 108 · see citing works

Effect of the genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers

Chung, J., Cho, J., YU, K., Kim, J., Jung, H., Lim, K. S., Jang, I., & Shin, S. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.02.006 · Cited by 105 · see citing works

Identification of Carboxylesterase-Dependent Dabigatran Etexilate Hydrolysis

Laizure, S. C., Parker, R. B., Herring, V. L., & Hu, Z. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054353 · Cited by 98 · see citing works

Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study

Testa, S., Legnani, C., Tripodi, A., Paoletti, O., Pengo, V., Abbate, R., Bassi, L., Carraro, P., Cini, M., Paniccia, R., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13486 · Cited by 87 · see citing works

Dabigatran Acylglucuronide, the Major Human Metabolite of Dabigatran: In Vitro Formation, Stability, and Pharmacological Activity

Thomas, E., Wagner, K., & Wienen, W. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033696 · Cited by 86 · see citing works

Dabigatran etexilate: A novel oral direct thrombin inhibitor

Blommel, M. L., & Blommel, A. L. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100348 · Cited by 66 · see citing works

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions

Shnayder, N. A., Петрова, М. М., Shesternya, P. A., Savinova, A. V., Николаевна, Б. Е., Zimnitskaya, O. V., Пожиленкова, Е. А., & Nasyrova, R. F. (2021) · Biomedicines · doi:10.3390/biomedicines9050451 · Cited by 38 · see citing works

Development and validation of LC–MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma

Nouman, E. G., Al‐Ghobashy, M. A., & LOTFY, H. M. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.02.042 · Cited by 36 · see citing works

Impact of cold storage on platelets treated with Intercept pathogen inactivation

Six, K. R., Devloo, R., Compernolle, V., & Feys, H. B. (2019) · Transfusion · doi:10.1111/trf.15398 · Cited by 35 · see citing works

Effects of 2 Concentrations of Sodium Citrate on Coagulation Test Results, von Willebrand Factor Concentration, and Platelet Function in Dogs

Morales, F., Couto, C. G., & Iazbik, M. C. (2007) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2007.tb02992.x · Cited by 25 · see citing works

Effects of 2 Concentrations of Sodium Citrate on Coagulation Test Results, von Willebrand Factor Concentration, and Platelet Function in Dogs

Morales, F., Couto, C. G., & Iazbik, M. C. (2007) · Journal of Veterinary Internal Medicine · doi:10.1892/0891-6640(2007)21[472:eocosc]2.0.co;2 · Cited by 24 · see citing works

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients

Moj, D., Maas, H. J., Schaeftlein, A., Hanke, N., Gómez‐Mantilla, J. D., & Lehr, T. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00776-y · Cited by 23 · see citing works

Real-time detection and differentiation of direct oral anticoagulants (rivaroxaban and dabigatran) using modified thromboelastometric reagents

Schäfer, S. T., Wiederkehr, T., Kammerer, T., Acevedo, A.-C., Feil, K., Kellert, L., Görlinger, K., Hinske, L. C., & Groene, P. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.019 · Cited by 23 · see citing works

Pharmacogenetics of Direct Oral Anticoagulants

Shnayder, N. A., Петрова, М. М., Николаевна, Б. Е., Zimnitskaya, O. V., Savinova, A. V., Пожиленкова, Е. А., & Nasyrova, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95966 · Cited by 12 · see citing works

Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions

Li, X., Liu, L., Xu, B., Xiang, Q., Li, Y., Zhang, P., Wang, Y., Xie, Q., Mao, Y., & Cui, Y. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.593 · Cited by 11 · see citing works

Effect of 3.2 vs. 3.8% sodium citrate concentration on anti-Xa levels for patients on therapeutic low molecular weight heparin

Payne, S. M., MacKinnon, K., Keeney, M., Morrow, B., & Kovacs, M. J. (2003) · Clinical & Laboratory Haematology · doi:10.1046/j.1365-2257.2003.00542.x · Cited by 9 · see citing works

New Oral Anticoagulants in Atrial Fibrillation

Conde, L. C., & Castro, J. L. (2013) · InTech eBooks · doi:10.5772/53614 · Cited by 7 · see citing works

Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model

Voigtlaender, M., Beckmann, L., Schulenkorf, A., Sievers, B., Rolling, C. C., Bokemeyer, C., & Länger, F. P. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15075 · Cited by 7 · see citing works

Development and validation of LC–MS/MS method for simultaneous determination of dabigatran etexilate and its active metabolites in human plasma, and its application in a pharmacokinetic study

Park, I.-H., Park, J., Chung, H., Kim, J., Lee, S., Kim, K., & Park, J. Y. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114220 · Cited by 7 · see citing works

The Effect of 3.2% and 3.8% Sodium Citrate on Specialized Coagulation Tests

Ratzinger, F., Lang, M., Belik, S., Schmetterer, K. G., Haslacher, H., Perkmann, T., & Quehenberger, P. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0200-oa · Cited by 5 · see citing works

GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis

Hooper, L., Liu, S., & Pai, M. P. (2025) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70007 · Cited by 32 · see citing works

Dabigatran attenuates methotrexate-induced hepatotoxicity by regulating coagulation, endothelial dysfunction, and the NF-kB/IL-1β/MCP-1 and TLR4/NLRP3 signaling pathways

El‐Dessouki, A. M., Alzokaky, A. A., Raslan, N. A., Ibrahim, S., Selim, H. M. R. M., & Al-Karmalawy, A. A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03567-w · Cited by 19 · see citing works

SLC4A4, FRAS1, and SULT1A1 Genetic Variations Associated With Dabigatran Metabolism in a Healthy Chinese Population

Xie, Q., Li, Y., Liu, Z., Mu, G., Zhang, H., Zhou, S., Wang, Z., Wang, Z., Jiang, J., Li, X., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.873031 · Cited by 8 · see citing works

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects

Chung, H., Kim, J.-M., Park, J., Noh, J., Kim, K., & Park, J. Y. (2023) · Pharmaceuticals · doi:10.3390/ph16030364 · Cited by 5 · see citing works

Modifications of the Prothrombin Active Site S4 Subpocket Confer Resistance to Dabigatran

Strijbis, V. J. F., Cheung, K. L., Veizaj, D., Rutten, T. A., Bruin, B., Reitsma, P. H., Verhoef, D., & Bos, M. H. A. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2537-6037 · Cited by 1 · see citing works

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran

Kim, J.-M., Bang, Y. Y., Kim, K., Park, J., & Park, J. Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-08417-0

In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate

Stassen, J., Priepke, H. W. M., Ries, U. J., Hauel, N. H., & Wienen, W. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-03-0183 · Cited by 250 · see citing works

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran

Kim, J.-M., Bang, Y. Y., Kim, K., Park, J., & Park, J. Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-08417-0

γT‐S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo

Sheffield, W. P., Lambourne, M. D., Eltringham‐Smith, L. J., Bhakta, V., Arnold, D. M., & Crowther, M. A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12601 · Cited by 14 · see citing works

Abstract 9928: Reversal of Anticoagulant Activity of Dabigatran and Dabigatran-induced Bleeding in Rats by a Specific Antidote (Antibody Fragment)

van Ryn, J., Litzenburger, T., & Schurer, J. (2012) · Circulation · doi:10.1161/circ.126.suppl_21.a9928 · Cited by 20 · see citing works

A specific antidote for dabigatran: functional and structural characterization

Schiele, F., van Ryn, J., Canada, K. A., Newsome, C., Sepulveda, E., Park, J., Nar, H., & Litzenburger, T. (2013) · Blood · doi:10.1182/blood-2012-11-468207 · Cited by 561 · see citing works